ARDX
Ardelyx, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.78
+1.89%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−40.0x
Market Cap
$975.95M
MomentumView details →
1D Return
+1.89%
YTD Return
−35.76%
RSI (14)
30.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−40.0x
Market Cap
$975.95M
RSI (14)
30.0
MomentumView details →
1D Return
+1.89%
YTD Return
−35.76%
SummaryUpdated Jun 1, 2026
Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company founded in 2007 and headquartered in Waltham, Massachusetts. Originally incorporated as Nteryx, Inc., the company changed its name to Ardelyx in June 2008 and went public in 2014. Ardelyx has evolved from a development-stage biotechnology company into a commercial-stage organization with two FDA-approved products addressing unmet medical needs in gastrointestinal and kidney-related conditions. The company has successfully transitioned from years of research and development losses to achieving profitability in 2024, marking a significant milestone in its corporate evolution.
Similar companies
Latest newsMore news →
Beam Therapeutics appointed Eric Foster as chief commercial officer.3d agoArdelux CFO Susan Hohenleitner sold 1,558 shares of ARDELYX common stock on August 21, 2026, in an automatic sell-to-cover transaction to satisfy tax withholding on RSU vesting, totaling approximately $6,009.10d agoJoseph James Reilly, Senior Vice President and Chief Accounting Officer of Ardelyx, Inc., sold 3,982 shares of company stock for $15,358 on August 21, 2026, to cover withholding taxes upon vesting of restricted stock units.10d ago